Literature DB >> 23509156

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

Katrin S Reiners1, Daniela Topolar, Alexander Henke, Venkateswara R Simhadri, Jörg Kessler, Maike Sauer, Martina Bessler, Hinrich P Hansen, Samir Tawadros, Marco Herling, Martin Krönke, Michael Hallek, Elke Pogge von Strandmann.   

Abstract

Natural killer (NK) cells are a major component of the anti-tumor immune response. NK cell dysfunctions have been reported in various hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here we investigated the role of tumor cell-released soluble and exosomal ligands for NK cell receptors that modulate NK cell activity. Soluble CLL plasma factors suppressed NK cell cytotoxicity and down-regulated the surface receptors CD16 and CD56 on NK cells of healthy donors. The inhibition of NK cell cytotoxicity was attributed to the soluble ligand BAG6/BAT3 that engages the activating receptor NKp30 expressed on NK cells. Soluble BAG6 was detectable in the plasma of CLL patients, with the highest levels at the advanced disease stages. In contrast, NK cells were activated when BAG6 was presented on the surface of exosomes. The latter form was induced in non-CLL cells by cellular stress via an nSmase2-dependent pathway. Such cells were eliminated by lymphocytes in a xenograft tumor model in vivo. Here, exosomal BAG6 was essential for tumor cell killing because BAG6-deficient cells evaded immune detection. Taken together, the findings show that the dysregulated balance of exosomal vs soluble BAG6 expression may cause immune evasion of CLL cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509156      PMCID: PMC3643764          DOI: 10.1182/blood-2013-01-476606

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.

Authors:  Alessandro Poggi; Claudia Venturino; Silvia Catellani; Marino Clavio; Maurizio Miglino; Marco Gobbi; Alexander Steinle; Paolo Ghia; Stefania Stella; Federico Caligaris-Cappio; Maria Raffaella Zocchi
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

2.  Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells.

Authors:  Robert Gastpar; Mathias Gehrmann; Maria A Bausero; Alexzander Asea; Catharina Gross; Josef A Schroeder; Gabriele Multhoff
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

3.  Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation.

Authors:  Janet North; Ismail Bakhsh; Chloe Marden; Hanna Pittman; Elena Addison; Cristina Navarrete; Robert Anderson; Mark W Lowdell
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Authors:  Massimo Vitale; Mariella Della Chiesa; Simona Carlomagno; Daniela Pende; Maurizio Aricò; Lorenzo Moretta; Alessandro Moretta
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

5.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

6.  Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Authors:  Woo Jae Kim; Ross A Okimoto; Louise E Purton; Meagan Goodwin; Sara M Haserlat; Farshid Dayyani; David A Sweetser; Andrea I McClatchey; Olivier A Bernard; A Thomas Look; Daphne W Bell; David T Scadden; Daniel A Haber
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

7.  Exosomes in Cancer Microenvironment and Beyond: have we Overlooked these Extracellular Messengers?

Authors:  Ruowen Ge; Evan Tan; Soheila Sharghi-Namini; Harry H Asada
Journal:  Cancer Microenviron       Date:  2012-05-15

8.  BAT3 regulates Mycobacterium tuberculosis protein ESAT-6-mediated apoptosis of macrophages.

Authors:  Ajay Grover; Angelo A Izzo
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

9.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

10.  Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function.

Authors:  Venkateswara Rao Simhadri; Katrin S Reiners; Hinrich P Hansen; Daniela Topolar; Vijaya Lakshmi Simhadri; Klaus Nohroudi; Thomas A Kufer; Andreas Engert; Elke Pogge von Strandmann
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

View more
  100 in total

1.  NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.

Authors:  Elke Pogge von Strandmann; Olga Shatnyeva; Hinrich P Hansen
Journal:  Ann Transl Med       Date:  2015-11

2.  Effects of methotrexate on the viscoelastic properties of single cells probed by atomic force microscopy.

Authors:  Mi Li; Lianqing Liu; Xiubin Xiao; Ning Xi; Yuechao Wang
Journal:  J Biol Phys       Date:  2016-07-20       Impact factor: 1.365

3.  Human dNK cell function is differentially regulated by extrinsic cellular engagement and intrinsic activating receptors in first and second trimester pregnancy.

Authors:  Jianhong Zhang; Caroline E Dunk; Melissa Kwan; Rebecca L Jones; Lynda K Harris; Sarah Keating; Stephen J Lye
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

4.  Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Authors:  Elisabetta Vulpis; Francesca Cecere; Rosa Molfetta; Alessandra Soriani; Cinzia Fionda; Giovanna Peruzzi; Giulio Caracciolo; Sara Palchetti; Laura Masuelli; Lucilla Simonelli; Ugo D'Oro; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rossella Paolini; Marco Cippitelli; Angela Santoni; Alessandra Zingoni
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

5.  Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Authors:  Julia Herrmann; Hannah Berberich; Jessica Hartmann; Steffen Beyer; Karen Davies; Joachim Koch
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

Review 6.  T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Authors:  C Russell Cruz; Catherine M Bollard
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

7.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 8.  Focus on exosomes: novel pathogenic components of leukemia.

Authors:  Chao Yang; Huan Yang; Jia Liu; Lidan Zhu; Shicang Yu; Xi Zhang; Lei Gao
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

9.  Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Authors:  Maulik Vyas; Ann-Charlott Schneider; Olga Shatnyeva; Katrin S Reiners; Samir Tawadros; Stephan Kloess; Ulrike Köhl; Michael Hallek; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2016-07-15       Impact factor: 8.110

10.  Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Authors:  Candida Vitale; Lorenzo Falchi; Elisa Ten Hacken; Hui Gao; Hila Shaim; Katrien Van Roosbroeck; George Calin; Susan O'Brien; Stefan Faderl; Xuemei Wang; William G Wierda; Katayoun Rezvani; James M Reuben; Jan A Burger; Michael J Keating; Alessandra Ferrajoli
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.